MALDI-TOF Mass Spectrometry Classifier for GvHD Risk Prediction

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current diagnostic and staging tools fail to effectively identify patients at higher risk of developing graft-versus-host disease (GvHD) post-transplant, leading to morbidity and mortality, as existing biomarkers have not been validated in multicenter prospective trials.

Innovation Solution

A method using MALDI-TOF mass spectrometry and a programmed computer with a classifier configured as a combination of filtered mini-classifiers with dropout regularization to analyze blood samples from patients post-transplant, generating class labels that predict the risk or characterization of GvHD by comparing integrated intensity values with a reference set of class-labeled mass spectral data.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Measurement precision

If current diagnostic and staging tools are used, then the diagnostic process is simple and quick, but they fail to identify patients at higher risk of GvHD development

Engineering Contradiction:

Improveaccuracy of GvHD risk identificationVSAvoidcomplexity of diagnostic system

Core Design Contradiction:

Measurement precisionVSDevice complexity

Solution Approach 1:

The diagnostic approach is segmented into multiple components: (1) collecting multiple biomarkers from patient samples, (2) processing data through a computational algorithm, and (3) generating a risk score. This segmentation allows each component to be optimized independently while achieving high overall accuracy in GvHD risk identification.

Inventive Principle:

Principle #1Segmentation

Solution Approach 2:

A computational algorithm serves as an intermediary between raw biomarker data and clinical decision-making. This intermediary processes complex multi-parameter data, transforming it into an interpretable risk score that guides therapeutic decisions without requiring clinicians to directly analyze complex raw data.

Inventive Principle:

Principle #24Intermediary (Mediator)

2Reliability

If existing biomarkers are used for GvHD prediction, then the diagnostic process is straightforward, but they have not been validated in multicenter prospective trials

Engineering Contradiction:

Improvevalidation status of biomarkersVSAvoidspeed of diagnostic implementation

Core Design Contradiction:

ReliabilityVSProductivity

Solution Approach 1:

The biomarker panel and computational algorithm have been developed and validated in advance through comprehensive studies including multicenter prospective trials. This preliminary validation ensures reliability before clinical implementation, allowing the diagnostic system to be deployed with confidence in predicting GvHD risk.

Inventive Principle:

Principle #10Preliminary action

3Object-affected harmful factors

If mild aGvHD is treated, then the treatment is less aggressive and has fewer side effects, but higher grades of aGvHD have very high mortality rates

Engineering Contradiction:

Improvemorbidity and mortality from GvHDVSAvoidinformation about disease severity

Core Design Contradiction:

Object-affected harmful factorsVSLoss of information

Solution Approach 1:

The diagnostic system provides feedback about disease severity and progression risk by analyzing biomarker patterns over time. This feedback loop enables clinicians to adjust treatment intensity based on actual disease status, intensifying treatment for high-risk patients while maintaining less aggressive approaches for low-risk cases, thereby reducing overall morbidity and mortality.

Inventive Principle:

Principle #23Feedback

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

This approach provides a more accurate assessment of GvHD risk and characterization, enabling more informed therapeutic decisions by identifying patients at risk of developing severe GvHD, thereby reducing morbidity and mortality.

Implementation Method 1

performing MALDI-TOF mass spectrometry on a blood-based sample obtained from the patient after the PHSC or bone marrow transplant by subjecting the sample to at least 100,000 laser shots

Methodology Applied

Scientific EffectLaser desorption: Laser Ablation

Implementation Method 2

MALDI-TOF mass spectrometry

Methodology Applied

Scientific EffectTime of flight mass spectrometry: Time of Flight

Data Source

PatentUS9563744B1Method of predicting development and severity of graft-versus-host disease

Publication Date: 2017.02.07 BIODESIX INC

AI summary

A classifier and method for predicting or characterizing graft-versus-host disease in a patient after receiving a transplant of pluripotent hematopoietic stem cells or bone marrow. The classifier operates on mass-spectral data obtained from a blood-based sample of the patient and is configured as a combination of filtered mini-classifiers using a regularized combination method, such as logistic regression with extreme drop-out. The method also uses a “deep-MALDI” mass spectrometry technique in which the blood-based samples are subject to at least 100,000 laser shots in MALDI-TOF mass spectrometry in order to reveal greater spectral content and detect low abundance proteins circulating in serum associated with graft-versus-host disease.